Curated News
By: NewsRamp Editorial Staff
September 03, 2026
Helus Pharma CEO to Present at Cantor Conference
TLDR
- Helus Pharma CEO's Cantor conference chat offers insider access to Phase 3 depression drug HLP003, a potential first-mover advantage.
- Helus Pharma develops novel serotonergic agonists targeting neuroplasticity; HLP003 in Phase 3 for MDD, HLP004 in Phase 2 for GAD.
- Helus Pharma aims to heal minds by advancing treatments for depression and anxiety, addressing unmet needs for better mental health.
- Helus Pharma, formerly Cybin, is pioneering psychedelic-inspired therapies, with CEO to speak at Cantor Healthcare Conference on Sept 11.
Impact - Why it Matters
This news matters because it highlights Helus Pharma's active engagement with the investment community, potentially increasing visibility and investor interest in their promising psychedelic-derived treatments for mental health. With Phase 3 data on HLP003 for major depressive disorder and a Breakthrough Therapy Designation, the company could significantly impact the treatment landscape if approved. Investors and patients alike should watch for updates from the conference as they may signal progress and future developments.
Summary
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference in New York City from Sept. 9-11, 2026. The webcast will take place on Sept. 11 at 8 a.m. EDT and will be available via replay on the company's investor relations website.
Helus Pharma, the commercial operating name of Cybin Inc., is focused on addressing mental health conditions such as depression and anxiety through proprietary NSAs that aim to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 trials for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. FDA. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. The company operates in Canada, the U.S., the U.K., and Ireland.
For more details, visit the full press release. The news was disseminated by PsychedelicNewsWire, a platform covering psychedelics and part of the Dynamic Brand Portfolio @ IBN. PsychedelicNewsWire provides news and content distribution to enhance brand awareness for companies in the sector.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Present at Cantor Conference
